ILiAD Biotechnologies

aid: iliad-biotechnologies
name: ILiAD Biotechnologies
description: 'ILiAD Biotechnologies, Inc. is a privately held, clinical-stage biotechnology company headquartered in Weston,
  Florida, developing BPZE1 — a live attenuated intranasal vaccine candidate designed to prevent Bordetella pertussis (whooping
  cough) colonization and transmission — alongside its B-Tech vector platform, which the company is exploring for infectious,
  allergic, autoimmune and neurodegenerative disease. The BPZE1 technology originated at Institut Pasteur de Lille and is
  exclusively licensed to ILiAD, which announced a $115M Series B in February 2026 and received a UK MHRA Innovation Passport
  designation in December 2024. ILiAD publishes a static corporate and scientific website only: as of 2026-08-22 it operates
  no public API, developer portal, SDK, machine-readable specification, or any other programmable surface.'
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://iliadbio.com/images/logo1.png
url: https://raw.githubusercontent.com/api-evangelist/iliad-biotechnologies/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-22'
modified: '2026-08-22'
tags:
- Company
- Biotechnology
- Vaccines
- Life Sciences
- Pharmaceuticals
- Health
- Immunology
- Infectious Disease
- Clinical Trials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://iliadbio.com/
- type: About
  url: https://iliadbio.com/company/overview.html
- type: News
  url: https://iliadbio.com/company/news.html
- type: Investors
  url: https://iliadbio.com/company/for-investors.html
- type: Careers
  url: https://iliadbio.com/careers.html
- type: ContactUs
  url: https://iliadbio.com/contact-us.html
- type: PrivacyPolicy
  url: https://iliadbio.com/privacy-policy.html
- type: DomainSecurity
  url: security/iliad-biotechnologies-domain-security.yml
- type: LLMsTxt
  url: llms/iliad-biotechnologies-llms.txt
- type: Team
  url: https://iliadbio.com/team/executive-board.html
- type: Product
  name: BPZE1 intranasal pertussis vaccine
  url: https://iliadbio.com/our_science/bpze1_vaccine.html
- type: Pipeline
  url: https://iliadbio.com/opportunity/pipeline.html
- type: Publications
  url: https://iliadbio.com/our_science/publications.html
x-enrichment:
  date: '2026-08-22'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: ILiAD Biotechnologies is a clinical-stage vaccine developer whose product is BPZE1, a live attenuated intranasal
    pertussis vaccine in human trials — not software — and iliadbio.com is an 88-page static HTML site of science, patent
    PDFs and press releases where /openapi.json, /graphql, /api-docs, /llms.txt and every /.well-known/ path return a real
    404, and api./docs./developer.iliadbio.com do not resolve in DNS.
  evidence:
  - url: https://iliadbio.com/openapi.json
    status: 404
  - url: https://iliadbio.com/graphql
    status: 404
  - url: https://iliadbio.com/.well-known/agent-card.json
    status: 404
  - url: https://iliadbio.com/llms.txt
    status: 404
  - url: https://iliadbiotech.com/.well-known/security.txt
    status: 404
  checked: '2026-08-22'